Self-Assembly Protein Nanogels for Safer Cancer Immunotherapy.
Soluble antigen-based cancer vaccines have poor retention in tissues along with suboptimal antigen processing by dendritic cells. Multiple booster doses are often needed, leading to dose-limiting systemic toxicity. A versatile, immunomodulatory, self-assembly protein nanogel vaccine is reported that induces robust immune cell response at lower antigen doses than soluble antigens, an important step towards biomaterials-based safer immunotherapy approaches.
Meinig School of Biomedical Engineering, College of Engineering, Cornell University, Ithaca, NY, 14853, USA.
Alberto
A
Purwada
Sibley School of Mechanical and Aerospace Engineering, College of Engineering, Cornell University, Ithaca, NY, 14853, USA.
Ye F
YF
Tian
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Weishan
W
Huang
Department of Material Science and Engineering, College of Engineering, Cornell University, Ithaca, NY, 14853, USA.
Kathleen M
KM
Rohrbach
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Simrita
S
Deol
Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY, 14853, USA.
Avery
A
August
Sibley School of Mechanical and Aerospace Engineering, College of Engineering, Cornell University, Ithaca, NY, 14853, USA.
Ankur
A
Singh
D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry / Q000276:immunology; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry*; D009363:Neoplasm Proteins / Q000737:chemistry / Q000276:immunology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D009363:Neoplasm Proteins
T cell; antigen; immunomodulation; immunotherapy; nanogels